---
title: "BFRI.US (BFRI.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BFRI.US/news.md"
symbol: "BFRI.US"
name: "BFRI.US"
parent: "https://longbridge.com/en/quote/BFRI.US.md"
datetime: "2026-03-08T02:20:51.640Z"
locales:
  - [en](https://longbridge.com/en/quote/BFRI.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BFRI.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BFRI.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/BFRI.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/BFRI.US/news.md)


# BFRI.US (BFRI.US) — Related News

### [U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable | BFRI Stock News](https://longbridge.com/en/news/277061338.md)
*2026-02-26T06:15:00.000Z*
> The U.S. Patent Trial and Appeal Board has ruled all challenged claims of Sun Pharma’s U.S. Patent No. 11,697,028 as unp

### [Biofrontera Raises 2025 EBITDA Outlook While Keeping Revenue Target](https://longbridge.com/en/news/275979244.md)
*2026-02-14T12:27:59.000Z*
> Biofrontera AG has raised its EBITDA forecast for fiscal 2025 to between EUR 3.5 million and EUR 5 million, up from EUR 

### [FDA Accepts Biofrontera sNDA Filing for Ameluz PDT in Superficial Basal Cell Carcinoma](https://longbridge.com/en/news/275619475.md)
*2026-02-11T14:15:18.000Z*
> Biofrontera Inc. announced that the FDA has accepted its supplemental New Drug Application for Ameluz® in combination wi

### [Pre-market hot trades in US stocks: BUUU pre-market down 9.57%; Biofrontera pre-market down 8.48%](https://longbridge.com/en/news/275441854.md)
*2026-02-10T10:37:33.000Z*
> BUUU pre-market down 9.57%; Biofrontera pre-market down 8.48%; Abpro pre-market up 86.18%; Haverty Furniture Companies, 

### [12 Health Care Stocks Moving In Monday's After-Market Session](https://longbridge.com/en/news/275362163.md)
*2026-02-09T21:05:50.000Z*
> In Monday's after-market session, several health care stocks experienced notable movements. Silexion Therapeutics (SLXN)

### [Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint | BFRI Stock News](https://longbridge.com/en/news/275330758.md)
*2026-02-09T06:15:00.000Z*
> Biofrontera Inc. announced positive results from its Phase 3 clinical trial of Ameluz® PDT for treating actinic keratose

### [Biofrontera reports successful Phase 3 study of Ameluz® PDT for AK on extremities, neck, trunk, meeting primary endpoint.](https://longbridge.com/en/news/275332810.md)
*2026-02-09T14:16:41.000Z*
> Biofrontera Inc. announced successful results from its Phase 3 study of Ameluz® PDT for treating mild to moderate actini
